As a result, considering the growing attention to ALK-RCC and the well-recognized benefit of ALK-i in other ALK-positive tumors [48], we aimed to systematically revise the available literature to evaluate the activity of ALK-i in ALK-RCC patients. The gene discussed is ALK; the disease is renal cell adenocarcinoma.